Zhang 2007a.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: eight weeks. Design: parallel. Location: inpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS total score of 60 or more. N = 50. Age: aripiprazole group: mean = (10.07 ± 2.35) years; risperidone group: mean = (9.37 ± 4.08) years. Gender: aripiprazole group: 11 Male, 14 Female; risperidone group: 10 Male, 15 Female . History: aripiprazole group: mean = (1.64 ± 3.74) months; risperidone group: mean = (1.87 ± 2.96) months. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐20 mg/day. Mean dose: not reported. N = 25. 2. Risperidone: Dose range: 1‐4 mg/day. Mean dose: not reported. N = 25.
Outcomes	Global state: PANSS score decreased rate (recovery: ≥ 75%, markedly improved: 50%‐75%, improved: 25%‐50%, no effect: < 25%). Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score, PANSS general psychogenic pathological subscale score. Adverse effects. Unable to use ‐ Adverse effects: blood and urine routines, EEG, use of anticholinergic drug and benzodiazepines (no data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	Data on blood and urine routines, EEG, use of anticholinergic drug and benzodiazepines were missing.
Other bias	Low risk	None obvious.